Industries > Pharma > Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2018-2028

Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2018-2028

Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services

PUBLISHED: 13 November 2018
PAGES: 213
PRODUCT CODE: PHA0340
SUBMARKET: Medical Devices

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0340 Categories: , Tags: , , , , ,

The Pre-Filled Device Manufacturing market is estimated to reach $7.5bn in 2022, growing at a CAGR of 10.5% from 2017 to 2022.

The majority of revenues for pre-filled syringe manufacturers, including component manufacturers and pen injector/autoinjector manufacturers, came from developed markets. In 2017, the US was the largest market for pre-filled injection devices, accounting for 39.9% of global revenues.

How this 213-page report delivers:

• Provides an overview and revenue forecasts of the global pre-filled injectable devices market from 2018 to 2028

• Profiles of selected leading companies in the pre-filled injection device manufacturing:
• Leading pre-filled syringe manufacturers
• Leading pre-filled injectable component manufacturers
• Leading pen injector and autoinjector manufacturers
• Leading pre-filled injectable devices contract manufacturers

• Companies profiled in this report:
• Aptar Stelmi
• Becton, Dickinson, & Co (BD)
• Bespak Injectables
• Boehringer Ingelheim
• Catalent
• Dätwyler Holding
• Gerresheimer
• Haselmeier
• Laboratorios Farmacéuticos ROVI
• Nemera
• Nipro
• Ompi
• Owen Mumford
• Roselabs Group.
• Schott
• SHL Group
• Tip-top
• Vetter Pharma
• Weigao Group Pharmaceutical Packaging Products Company
• West Pharmaceutical Services.
• Ypsomed

Top Pre-Filled Injection Device Manufacturers 2018-2028

• Information provided for the selected leading companies, when available:
• Overview of the company
• Historical Revenues
• Revenue forecasts from 2018-2028
• A SWOT analysis
• A competitive analysis
• Products & Services
• Business Developments: Expansion, new products, mergers, acquisitions, collaborations.

• This report also discusses the key trends in the pre-filled injection device manufacturing market.

101 charts unavailable elsewhere

Visiongain’s study is intended for anyone requiring commercial analyses for the pre-filled injection device manufacturing market. You find data, trends and predictions.

Buy our report today Top Pre-Filled Injection Device Manufacturers 2018-2028: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2018-2028


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category